Most Cited Papers In Last Two Years

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Anti-BCMA novel therapies for multiple myeloma

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment

Nano-TRAIL: a promising path to cancer therapy

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Emerging roles of 3D-culture systems in tackling tumor drug resistance

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment